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S298 Poster Session II(IL-1b, IL-6, IL-8, IFN-g, MIF and TNF-a). We have observed
clinical differences in the rates of mixed chimerism and GVHD de-
pending on when the alemtuzumab is given. This data suggests that
the cytokine milieu may contribute to the development of GVHD
and Transplant Related Morbidity (TRM).
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION IN COMMUNITY CANCER CENTERS: SINGLE INSTITUTION EXPE-
RIENCE
Khaled, Y., Beredo, L., McEntee, S., Fondaw, M., Villegas, M.,
Mountford, K., Reddy, V. Florida Cancer Institute, Orlando, FL
Variability in outcomes after hematopoietic stem cell transplanta-
tion (HCT) due to differences in health care delivery is traditionally
referred to as ‘‘center effect’’. Data analysis by CIBMTR demon-
strated improved day 100 survival after related donor (RD) HCT
with greater physician involvement in patient’s care regardless of
medical school affiliation. We hypothesized that the greater physi-
cian involvement in patient’s care at our community transplant cen-
ter would compensate for the lack of infrastructure available to
academic centers and result in comparable outcomes.We retrospec-
tively reviewed the medical records of 50 consecutive patients who
underwent matched unrelated (MUD) HCT (n 5 26) or RD HCT
(n 5 24) for hematological malignancies between August 2007 andTable 1. Patients characteristic
Number of patients 50 (100%)
Age Median 56 (Range 23-71)
Patients above the age of 55 27 (54%)
Patients below the age of 55 23 ( 46%)
Match related (RD) 23 (46%)
Mismatched related 5/6 1 (2%)
Matched unrelated (MUD) 22 (44%)
Mismatched unrelated 4 (8%)
Male 30 (60%)
Female 20 (40%)
Diagnosis
AML/MDS 26 (52%)
ALL 8 (16%)
Myelofibrosis 2 (4%)
CLL 2 (4%)
T-cell prolymphocytic leukemia 2 (4%)
CML (accelarated phase) 1 (2%)
HD 2 (4%)
Severe aplastic anemia 1 (2%)
Non Hodgkins lymphoma 3 (6%)
Multiple myeloma 3 (6%)
Stem cell source Peripheral stem cells 50 (100%)
Status at transplant
Complete remission -1 20 (40%)
Complete remission-2 9 (18%)
Progressive disease 7 (14%)
Persistent disease 14 (28%)
Prior Transplants
Autologous 7; non tandem (14%)
Allogeneic related 5 (10%)
Cytogenetics
High Risk 28 (56%)
Normal 19 (38%)
Not available 3 (6%)
Charlson Comorbidity Index
Score 0 7 (14%)
Score 1-2 10 (20%)
Score 3-4 20(40%)
Score 5 and above 13 (26%)
Conditioning Regimens
Full Intensity (FIC) 20 (40%)
Reduced Intensity(RIC) 21(42%)
Non Myeloablative (NMA) 9 (18%)
GVHD, graft versus host disease; OS, overall survival; DFS, disease free
survival; NRM, non relapse mortality; NMA, Flu/TBI, RIC, FluBU-2/Flu-
Mel, FIC FluBU-4/BUCY/CYTBIApril 2010. GVHD prophylaxis used was Tacrolimus/Methotrexate
or Tacrolimus/Mycophenolate. MUD HCT recipients recieved
ATG in addition. Twenty one (42%) and twenty eight patients
(56%) of cohort had progressive/persistent disease and high risk cy-
togenetics at time of transplant respectively. Thirty three patients
(66%) had Charlson Co-morbidity index of 3 or more. Patients
characteristic is shown in the table below.
OS at 100 days and 1 year were 86% and 67% respectively. There
was no statistical difference in OS between RD and MUD; (83% vs.
88% at day 100 and 74% vs. 64% at 1 year for RD and MUD recip-
ients respectively, P5 0.85). DFSwas 55% at 1year. Again, there was
no statistical significance difference in DFS between RD and MUD
at 1 year (P5 0.48). The cumulative incidence of relapse was 16% at
1 year (21% for RD and12% for MUD). We found no difference in
the cumulative incidence of NRMbetween RD andMUD recipients
at day 100 (12%). In contrast, NRM was higher at 1 year in MUD
recipients of 34% vs. 25% for the RD recipients. The overall cumu-
lative incidence of acute GVHD grade II-IV was 47.8% with inci-
dence of severe GVHD grade III/IV of 16%. The cumulative
incidence of chronic GVHD was 67.6%.
Conclusions: Allogeneic HCT outcomes in the community seem to
be comparable to outcomes reported in literature. In this single in-
stitution experience, despite the absence of direct cause and effect re-
lationship, the greater involvement of physicians in the patient’s care
may have contributed to the improved outcomes in this high risk co-
hort of patients. Community transplant centers may contribute in
the future to meet the increased demands for allogeneic HCT with
reasonable outcomes.
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PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINEWITH PAR-
ENTERAL BUSULFAN (CLO/BU) FOLLOWED BY ALLOGENEIC RELATED
OR UNRELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
Agura, E.1,2, Berryman, R.B.1,2, Pineiro, L.1,2, Vance, E.1,2, Tadic-
Ovcina, M.1, Woelfel, R.G.1, Fay, J.1,2 1Charles A Sammons Cancer
Center, Baylor University Medical Center, Dallas, TX; 2Charles A
Sammons Cancer Center, Texas Oncology P.A., Dallas, TX
BACKGROUND: RIT regimens are common, but relapse remains
a problem. We proposed and tested a mid-intensity regimen using
clofarabine (CLO) with busulfan (BU).We hypothesized this combo
would be well tolerated and offer greater anti-leukemic efficacy than
existing RIT regimens.
METHODS:We enrolled 20 patients on this single IST, with AML
(10), ALL (1), CLL (1),MDS (2) andMDS-AML (6). 15 patients had
prior therapies. The regimenwas: CLO40mg/m2 iv daily x5, BU 3.2
mg/kg iv daily x2, followed by 1 rest day, followed byHSCT.Donors
were matched at A, B, C, DR, DQ usingDNA SBT or mid-res DNA
typing. Mismatch# 1 antigen was allowed. GVHD prophylaxis was
FK506 and MTX 5mg/m2 iv (d 1,3,6).
RESULTS: Endpoints included toxicity, engraftment, incidence/
severity of AGVHD, and disease response.
All patients experienced grade 4 hem tox.Median time to ANC re-
covery (18/20 patients used GCSF) was 13 days (d9 - d17). Engraft-
ment (. 80% donor chim. at d30) occurred in all patients by FISH
and/or STR. Selected tox. included; 2 patients - hand/foot syndrome
(1 Gr. 3, REL.); 1 resp. failure (Gr. 3 poss. REL) resolved com-
pletely; 5 patients - elevated ALT/AST (Gr.3-4, REL) resolving at
regimen completion; other tox. were#Gr. 2. TRMwas non-existent
in this study.
18 patients developed AGVHD by d100 – 83% grade 1-2; 17%
grade 3-4. No deaths attributed to AGVHD following study regi-
men.
Disease responses are: 11 (58%) patients, in relapse/active disease
prior to CLO/BU, achieved CR by d30. 7 (37%) patients in CR at
study entry, remained so at d30. 1 patient was N/E for disease re-
sponse at d30. 1 patient (w / CLL) achieved CR at d132. 7 (37%) pa-
tients relapsed (M. d120 (d60 – d699)). 12 (60%) patients expired (M.
d222 (d92 – d438)): cardiac arrest (1, d316); asp. pneumonia (1,
d158); TTP (1, d438); AGVHD - post DLI (1, d175); relapse (4,
M. d192 (d150 – d415)); persistent disease (1, d161); MSOF (1,
d92); ITP (1, d307); Pulmonary Embolus (1, d233). Of 19 evaluable
patients, 6 (32%) remain in remission with a median follow up of 946
days (31 months) (d396 – d1236).
